How it works:
Inhibits replication of hepatitis C virus
Acts as an NS5A protein inhibitor critical for viral replication
Reduces viral load
Enhances effectiveness of combination antiviral therapy
Recommended for:
Patients with confirmed hepatitis C
Use with other antiviral agents such as sofosbuvir
Suitable for co-infected HIV patients or those with liver cirrhosis (under medical supervision)
Chronic hepatitis C infection in adults as part of combination therapy with other antiviral drugs.
DACLAHEP is taken orally once daily with or without food. Treatment duration and combinations are determined by a healthcare professional based on HCV genotype and overall patient condition.
Contraindications:
Hypersensitivity to daclatasvir
Age under 18
Pregnancy and breastfeeding
Concomitant use with strong CYP3A inducers
Side effects:
Fatigue, headache
Nausea
Diarrhoea
Insomnia
Anaemia (in combination therapy)